Multimedia Capabilities
•
E-Newsletters
- E-TOCs
- Sponsored E-Newsletter
•
Custom Conference
Coverage
•
Live Events /
Advisory Boards
•
Microsite
•
Audiocast
•
Product Showcase
•
Special Features
•
Sponsored Online Poll
•
Sponsored Online
Survey
•
Supplements
- Print
- Digital Edition
•
Webcast
•
Web Advertising
- Collections
- Web site
- E-TOCs
- Digital Edition
Career Center
Contact Us
Advanced Search
My Account
|
Register
Home
Current Issue
•
Editorial
•
Upcoming Articles
Archives
•
Search Archives
•
Past Issues
•
Yearly Index
Topic Collections
Medical Education
•
Online CME
•
PTMG
Sponsored Programs
Patient Resources
Multimedia
•
Webcast
•
Audiocast
Information
About Us
- About Cutis
- Company
- Permissions
- Editorial Board
- Contact Us
Author Guidelines
- Info for Authors
- Manuscript Status
- Letters to the Editor
Advertisers' Info
- Reprints
- Advertising Info
- Media Kit
- Classified Rate Card
Subscriptions
•
New Subscription
•
Renew Subscription
•
Single Issue
•
Online Subscription
•
24hr/3day/7day Access
•
Single Article Access
•
Site License
ADVERTISEMENT
Home
Article
Email
Print
Download
+ More
Text
RSS Feed
Department
Drug Therapy Topics
Newer Topical Therapies for the Treatment of Acne Vulgaris
Del Rosso JQ
Cutis
. 2007;80:400-410.
Newer topical therapies approved by the US Food and Drug Administration (FDA) for the treatment of acne vulgaris are dapsone gel 5% and clindamycin phosphate 1.2% and tretinoin 0.025% combination gel. Both are formulated in aqueous-based gel vehicles. These newer topical acne products have been shown to be effective and safe in pivotal 12-week phase 3 trials and long-term studies completed over 12 months. This article reviews applicable pharmacokinetic, efficacy, and safety data reported with both products.
[
PDF
|
Buy Article
|
Add to My Archive
]
RELATED ARTICLE(S)
Male Acne: The Importance of Gender in Acne Treatment [editorial]
Efficacy and Tolerability of Fixed-Combination Acne Treatment in Adolescents
Clindamycin Phosphate 1.2%–Benzoyl Peroxide (5% or 2.5%) Plus Tazarotene Cream 0.1% for the Treatment of Acne
Phototoxic and Photoallergic Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch Studies
Cumulative Irritation Potential and Contact Sensitization Potential of Tazarotene Foam 0.1% in 2 Phase 1 Patch Studies
Randomized, Observer-Blind, Split-Face Study to Compare the Irritation Potential of 2 Topical Acne Formulations Over a 14-Day Treatment Period
Is it Acne or Is it Rosacea? An Important Distinction [editorial]
Effects of Topical Retinoid Therapy on Acne Lesions: A Psychometric Assessment
Acne and Rosacea: Epidemiology, Diagnosis, and Treatment [book review]
A Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of 2 Treatments in Participants With Mild to Moderate Acne Vulgaris
Email
Print
Order Reprints
Share:
Already a print Subscriber?
Activate
to get full subscriber access to our Web site.
Missing and Damaged Issues
Must be claimed within 3 months of the cover date to qualify for a replacement, without charge.
FOR ALL NEW SUBSCRIPTIONS, RENEWALS, CHANGES OF ADDRESS, AND CANCELLATIONS
Subscription Customer Service
Please call 1-800-480-4851
Fax: 1-866-556-5909 or 516-908-3802
E-mail:
quadrantcut@emscirc.com
Technical Support
9 am to 5 pm EST, Mon. - Fri.
dilip.dorwani@qhc.com
FOR ALL NEW SUBSCRIPTIONS, RENEWALS, CHANGES OF ADDRESS, AND CANCELLATIONS
Please call (973)206-8018.
YOUR ACCESS TO ONLINE, FEATURING
Searching and reading archived articles from 2000 to present
Print, download, and save articles
Receive personalized e-mail alerts
Subscription to our monthly E-newsletter
YOUR ACCESS TO ONLINE ARTICLE, FEATURING
Ability to print, download, and save article
Share high-quality PDF with colleagues
Access to receive personalized e-mail alerts
Subscription to our monthly E-newsletters
BENEFITS OF SUBSCRIBING
Each year, you will receive 12 print issues of
Cutis
®
, which provides timely, unbiased, and practical information to enhance the day-to-day care of Cutis. In each issue, you will find:
Original clinical articles
Informative case reports
Expert review articles
Timely editorials and departments
Diagnostic clinical images
In addition to the regular edition,
Cutis
®
periodically publishes sponsored Supplements for the benefit of its readers
Your subscription also includes full access to online features, including:
Unlimited access to archived articles from 2000 to present
Ability to print, download, and save articles
Access to personalized e-mail alerts
Subscription to our monthly e-newsletters
BENEFITS OF SUBSCRIBING
Your subscription includes full access to
Cutis
®
online, featuring 12 online/digital issues of the print journal, which include:
Original clinical articles
Informative case reports
Expert review articles
Timely editorials and departments
Diagnostic clinical images
Your subscription also includes full access to
Cutis
®
online, including:
Unlimited access to archived articles from 2000 to present
Ability to print, download, and save articles
Access to personalized e-mail alerts
Subscription to our monthly e-newsletters
BENEFITS OF SUBSCRIBING
Ability to print, download, and save article
Ability to share high-quality PDF with colleagues
Access to receive personalized e-mail alerts
Subscription to our monthly e-newsletters
CUSTOMER SERVICE
FOR ALL NEW SUBSCRIPTIONS, RENEWALS, CHANGES OF ADDRESS, AND CANCELLATIONS
Subscription Customer Service
9 am to 5 pm EST Mon. - Fri.
Phone: 1-800-480-4851
Fax: 1-866-556-5909 or 516-908-3802
quadrantcut@emscirc.com
FOR TECHNICAL SUPPORT
9 am to 5 pm EST Mon. - Fri.
dilip.dorwani@qhc.com
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
Quick Poll
Which social media tool do you use most often to reach patients?
A.
B.
A. blog
B. Facebook
C. Twitter
D. Web site
Submit Answer
View Results
ADVERTISEMENT
Breaking News
clientId = "FD1B4C99"; newsFeed = "P"; newsType = "24"; category = "3"; numberReturn = "4"; landingUrl = "Physician-Brief-News-Article.aspx";
More News
Most Popular
Most Viewed
Standard Management Options for Rosacea, Part 1: Overview and Broad Spectrum of Care
Current Regimens and Guideline Implications for the Treatment of Actinic Keratosis: Proceedings of a Clinical Roundtable at the 2011 Winter Clinical Dermatology Conference
Standard Management Options for Rosacea, Part 2: Options According to Subtype
Optimizing Topical Therapies for Treating Psoriasis: A Consensus Conference
The ORCA (Oracea
®
for Rosacea: A Community-Based Assessment) Trial: A Large-Scale, Phase 4 Trial in Papulopustular Rosacea
Most Archived
Most Downloaded
Most E-mailed
Most Viewed Collections
Top Search Terms
Month
Week
Week 1
Week 2
Week 3
Week 4
Week 5
Register
|
My Account
|
Home
|
Current Issue
|
Archives
|
Topic Collections
|
Medical Education
|
Sponsored Programs
|
Patient Resources
|
Multimedia
|
Information
|
Subscriptions
About Us
Terms of Use
Privacy Policy
Site Map
Customer Service
Advertise With Us
Career Center
Multimedia Capabilities
Contact Us
Frontline Medical Communications Inc. Publications
:
The American Journal of Orthopedics
|
Chronic Pain Perspectives
|
Clinician Reviews
|
Cosmetic Dermatology
Current Psychiatry
|
Cutis
|
Emergency Medicine
|
Federal Practitioner
|
The Female Patient
|
The Journal of Family Practice
Neurology Reviews
|
OBG Management
|
Physician's Travel & Meeting Guide
Frontline Medical Communications Inc. Websites
:
Metabolic and Endocrine Disease Summit
|
Current Psychiatry/ American Academy of Clinical Psychiatrists Update
Female Urology and Urogynecology Symposium
|
Pelvic Anatomy and Gynecologic Surgery Symposium
|
Emerging Techniques in Orthopedics, Sports Medicine & Arthroscopic Surgery
|
Minimally Invasive Surgery Symposium
|
Psychiatry for Primary Care Clinicians
|
Psychopharmacology Update
|
Generational Dermatology Summit